Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 2/20 | 0.63 |
| ▸ | JAK1 | P23458 | 6/20 | 0.44 |
| ▸ | BRD4 | O60885 | 5/20 | 0.44 |
| ▸ | JAK2 | O60674 | 3/20 | 0.44 |
| ▸ | JAK3 | P52333 | 3/20 | 0.44 |
| ▸ | ULK1 | O75385 | 1/20 | 0.43 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 2/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.40 |
| ▸ | MERTK | Q12866 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3496305 | 0.89 | PRKCQ (0.60) | PRKCQBRD4ULK1ULK2IGF1R | |
| SCHEMBL3495607 | 0.88 | PRKCQ (0.59) | PRKCQJAK1BRD4JAK2JAK3 | |
| SCHEMBL3492920 | 0.88 | PRKCQ (0.75) | PRKCQBRD4ULK1ULK2SYK | |
| SCHEMBL3496953 | 0.88 | PRKCQ (0.59) | PRKCQBRD4ULK1ULK2IGF1R | |
| SCHEMBL3495644 | 0.88 | BRD4 (0.55) | PRKCQJAK1BRD4JAK2JAK3 | |
| SCHEMBL3494857 | 0.87 | PRKCQ (0.50) | PRKCQJAK1BRD4JAK2JAK3 | |
| SCHEMBL3495246 | 0.87 | PRKCQ (0.85) | PRKCQJAK1BRD4JAK2JAK3 | |
| SCHEMBL3494403 | 0.86 | PRKCQ (0.57) | PRKCQBRD4ULK1ULK2IGF1R | |
| SCHEMBL3496516 | 0.86 | PRKCQ (0.57) | PRKCQBRD4ULK1ULK2IGF1R | |
| SCHEMBL3496345 | 0.86 | ULK1 (0.62) | PRKCQULK1ULK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | claimed |
| EP-2183225-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | claimed |
| WO-2009012421-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | claimed |
| US-8993585-B2 | Cyclic amine substituted pyrimidinediamines as PKC inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| EP-2183225-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009012421-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | PRKCH, PKD2, PRKCQ | PRKCQ 3/4885JAK1 292/4885BRD4 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.